Workflow
CCHT(000661)
icon
Search documents
长春高新2025年中报简析:净利润同比下降42.85%
Zheng Quan Zhi Xing· 2025-08-30 23:25
据证券之星公开数据整理,近期长春高新(000661)发布2025年中报。根据财报显示,长春高新净利润 同比下降42.85%。截至本报告期末,公司营业总收入66.03亿元,同比下降0.54%,归母净利润9.83亿 元,同比下降42.85%。按单季度数据看,第二季度营业总收入36.05亿元,同比上升4.16%,第二季度归 母净利润5.1亿元,同比下降40.75%。 本次财报公布的各项数据指标表现不尽如人意。其中,毛利率83.35%,同比减1.5%,净利率14.11%, 同比减47.82%,销售费用、管理费用、财务费用总计31.01亿元,三费占营收比46.97%,同比增28.5%, 每股净资产55.98元,同比增3.27%,每股经营性现金流2.99元,同比减38.78%,每股收益2.44元,同比 减42.99% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 66.39 Z | 66.03亿 | -0.54% | | 归母净利润(元) | 17.2 Z | 9.83 6 | -42.85% | | 扣非净利润(元) | ...
长春高新:上半年研发投入同比增长17.32% 高潜力产品布局加速推进
Zhong Zheng Wang· 2025-08-30 04:42
Core Insights - Changchun High-tech reported a revenue of 6.603 billion yuan and a net profit of 983 million yuan for the first half of 2025, reflecting a strong focus on R&D and product innovation [1] - The company increased its R&D investment to 1.335 billion yuan, a 17.32% year-on-year growth, with R&D expenses accounting for 20.21% of total revenue [1] - Key subsidiary Jin Sai Pharmaceutical is engaged in the development of innovative drugs and has launched the first domestically approved IL-1β monoclonal antibody, enhancing its product portfolio in autoimmune diseases [1] R&D and Product Development - The company is enhancing its product pipeline by focusing on high-demand therapeutic areas such as oncology, immunology, and respiratory diseases, while maintaining a strong position in pediatric and women's health [2][3] - Changchun High-tech is leveraging AI technology to improve drug research efficiency and has developed multiple innovative drug candidates across various therapeutic modalities [2][3] - The company has established several core technology platforms with independent intellectual property rights, covering the entire process of innovative drug design and development [3] Strategic Goals and Market Position - The company aims to become a globally influential biopharmaceutical group, focusing on innovation in the health sector and enhancing brand value and market presence [4] - Changchun High-tech is transitioning from a "single blockbuster" strategy to a diversified innovation approach, with multiple promising products in the pipeline supporting long-term growth [3] - The company is committed to increasing investment in innovative technologies and projects while optimizing cost management to ensure sustainable and healthy development [4]
长春高新上半年研发投入同比增长17.32% 加速从单一产品向多元化布局
Zheng Quan Ri Bao· 2025-08-30 03:40
Core Viewpoint - Changchun High-tech's revenue and net profit have declined in the first half of 2025, attributed to strategic adjustments and increased innovation investments [2] Financial Performance - In the first half of 2025, the company achieved revenue of 6.603 billion yuan, a year-on-year decrease of 0.54% [2] - The net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [2] - Research and development (R&D) investment reached 1.335 billion yuan, an increase of 17.32% compared to the same period last year, with R&D expenses accounting for 20.21% of revenue [2] Strategic Initiatives - The company is transitioning from a single product focus to a diversified layout, emphasizing technology innovation as a core driver of development [2] - Changchun High-tech is leveraging artificial intelligence (AI) to enhance drug research and has established seven enterprise-level intelligent platforms to promote digital transformation [2][3] Product Development - In the growth hormone sector, Changchun High-tech maintains a leading market share in China, with its subsidiary, Changchun Jinsai Pharmaceutical, generating revenue of 5.469 billion yuan, a 6.17% increase year-on-year [3] - The company has launched its first innovative drug for gout treatment, Jinbeixin® (伏欣奇拜单抗), which is the first fully human monoclonal antibody targeting IL-1β in China [5] - Changchun High-tech is expanding its innovative gene engineering pharmaceutical business, focusing on children's and women's health, as well as key areas like endocrine metabolism and oncology [4] Future Outlook - The company plans to continue its focus on the pharmaceutical industry, increasing R&D investments and introducing cutting-edge products and technologies, while targeting high-burden diseases prevalent in both China and the U.S. [5]
长春高新:8月28日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-08-29 18:35
Company Overview - Changchun High New Technology Industry Group Co., Ltd. (SZ 000661) announced on August 30 that its 11th Board of Directors meeting was held on August 28, 2025, to discuss the proposal for issuing H-shares and listing on the Hong Kong Stock Exchange [1] Financial Performance - For the first half of 2025, the revenue composition of Changchun High New was as follows: Pharmaceutical industry accounted for 92.83%, Real estate accounted for 6.81%, and Service industry accounted for 0.36% [1]
长春高新(000661.SZ)发布上半年业绩,归母净利润9.83亿元,同比下降42.85%
智通财经网· 2025-08-29 16:02
智通财经APP讯,长春高新(000661.SZ)发布2025年半年度报告,报告期内,公司实现营业收入66.03亿 元,同比下降0.54%。实现归属于上市公司股东的净利润9.83亿元,同比下降42.85%。实现归属于上市 公司股东的扣除非经常性损益的净利润10.33亿元,同比下降40.55%。基本每股收益2.44元。 ...
长春高新上半年研发投入逆势增长17% 创新驱动成效加速显现
Core Viewpoint - The company reported a revenue of 6.603 billion yuan and a net profit of 983 million yuan for the first half of 2025, indicating short-term performance pressure due to increased R&D investment and market competition, but long-term resilience is expected as innovation results materialize [1] Group 1: Innovation and R&D - The company has emphasized an innovation-driven development strategy, with R&D investment increasing by 17.32% year-on-year to 1.335 billion yuan, accounting for 20.21% of revenue [2] - The approval of the new drug Fuxin Qibai monoclonal antibody (trade name: Jinbeixin) for acute gouty arthritis is a significant highlight, addressing a large patient population in China [2] - The drug offers clinical advantages such as long-term control, rapid efficacy, and safety, filling a gap in long-acting anti-inflammatory targeted therapies [2] Group 2: Product Pipeline and Market Expansion - The company is expanding the indications for Fuxin Qibai monoclonal antibody, with ongoing clinical trials for various conditions, which may become a new growth driver [3] - Jin Sai Pharmaceutical is enhancing its product pipeline in multiple disease areas, focusing on high-demand and high-potential therapeutic fields, including oncology and immunology [3] Group 3: AI Integration and Development - The company is leveraging AI to enhance R&D efficiency, achieving significant improvements in molecular design and process optimization [5] - Seven AI platforms have been established to support various business needs, including drug development and marketing [5] Group 4: Strategic Initiatives and Global Expansion - The company plans to issue H-shares and list on the Hong Kong Stock Exchange, which is expected to deepen its global strategy and accelerate internationalization [7][8] - The listing aims to help the company build a globally influential biopharmaceutical group [8]
长春高新上半年营收66.03亿元同比降0.54%,归母净利润9.83亿元同比降42.85%,毛利率下降1.27个百分点
Xin Lang Cai Jing· 2025-08-29 15:31
Core Viewpoint - Changchun High-tech reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its business performance [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 6.603 billion yuan, a year-on-year decrease of 0.54% [1]. - The net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [1]. - The basic earnings per share were 2.44 yuan [2]. - The gross profit margin for the first half of 2025 was 83.35%, a decrease of 1.27 percentage points year-on-year [2]. - The net profit margin was 14.11%, down 12.93 percentage points compared to the same period last year [2]. Cost and Expenses - Total operating expenses for the first half of 2025 were 4.256 billion yuan, an increase of 943 million yuan year-on-year [2]. - The expense ratio was 64.46%, up 14.55 percentage points from the previous year [2]. - Sales expenses increased by 23.43%, management expenses by 31.26%, R&D expenses by 30.22%, and financial expenses surged by 85.44% [2]. Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 109,100, a decrease of 16,000 or 12.78% from the previous quarter [2]. - The average market value per shareholder increased from 318,900 yuan to 370,800 yuan, a growth of 16.28% [2]. Company Overview - Changchun High-tech, established on June 10, 1993, and listed on December 18, 1996, is located in Changchun, Jilin Province [3]. - The company primarily engages in the research, production, and sales of biopharmaceuticals and traditional Chinese medicine, with real estate development and property management as supplementary businesses [3]. - The revenue composition includes 88.40% from biopharmaceuticals, 5.66% from traditional Chinese medicine, 5.61% from real estate, and 0.32% from services [3].
长春高新上半年研发投入同比增长17.32% 布局多个高需求及高潜力治疗领域
Core Insights - Changchun High-tech reported a revenue of 6.603 billion yuan and a net profit attributable to shareholders of 983 million yuan for the first half of 2025 [1] - The company focuses on biopharmaceuticals and traditional Chinese medicine, with a diversified portfolio including gene engineering, biological vaccines, and modern Chinese medicine [1][2] Financial Performance - In H1 2025, the subsidiary Jinsai Pharmaceutical achieved a revenue of 5.469 billion yuan, a year-on-year increase of 6.17%, but its net profit decreased by 37.35% to 1.108 billion yuan [1] - Baike Bio reported a revenue of 285 million yuan, down 53.93%, with a net loss of 74 million yuan [1] - Huakang Pharmaceutical's revenue was 378 million yuan, a decrease of 3.40%, while its net profit increased by 4.12% to 25 million yuan [1] - Gaoxin Real Estate generated a revenue of 460 million yuan, up 0.76%, but its net profit dropped by 70.34% to 10 million yuan [1] R&D Investment - The company invested 1.335 billion yuan in R&D, a 17.32% increase year-on-year, with R&D expenses reaching 1.155 billion yuan, up 30.22% [2] - R&D investment accounted for 20.21% of total revenue, reflecting a strategic focus on innovation and product development [2] - The increase in R&D spending is attributed to accelerated new product development and enhanced talent acquisition efforts [2] Strategic Focus - The company is strengthening its product layout in endocrine metabolism and pediatric fields, targeting high-demand therapeutic areas such as oncology, immunology, and respiratory diseases [3] - This strategic focus aims to support sustainable development and diversification while pursuing internationalization [3]
长春高新:上半年归母净利润9.83亿元,同比下降42.85%
Xin Lang Cai Jing· 2025-08-29 15:11
Group 1 - The company reported a revenue of 6.603 billion yuan for the first half of the year, representing a year-on-year decrease of 0.54% [1] - The net profit attributable to shareholders of the listed company was 983 million yuan, showing a year-on-year decline of 42.85% [1] - The basic earnings per share were 2.44 yuan [1]
长春高新(000661) - 总经理工作细则
2025-08-29 13:48
证券代码:000661 证券简称:长春高新 公告编号:2025-084 长春高新技术产业(集团)股份有限公司 总经理工作细则 经第十一届董事会第十一次会议审议通过 | | | 第一章 总则 第一条 为进一步完善长春高新技术产业(集团)股份有限公司 (以下简称"公司")法人治理结构,明确总经理的职责、权限,规 范总经理的职务行为和总经理议事程序,根据《中华人民共和国公司 法》(以下简称"公司法")、《上市公司治理准则》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法 规、规范性文件和《公司章程》等有关规定,制定本细则。 第二章 总经理的任职资格与任免程序 第二条 总经理任职应当具备下列条件: (一)具有较丰富的经济理论知识、管理知识及实践经验,具有 较强的经营管理能力; 3 (四)担任因违法被吊销营业执照、责令关闭的公司、企业的法 定代表人,并负有个人责任的,自该公司、企业被吊销营业执照、责 令关闭之日起未逾三年; (五)个人所负数额较大的债务到期未清偿被人民法院列为失信 被执行人; (二)具有较强的组织、协调能力; (三)具有五年以上企业管理或经济管理工作经历,掌握国家有 关 ...